SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that it has received conditional marketing authorization

The dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice.

Johns Hopkins investigators are testing a way to use drugs that target a cholesterol pathway to enhance the cancer-killing potential of standard chemotherapy drugs.

The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found.

Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar)—the chemotherapy drug that is considered standard therapy for the disease.